title: Calycosin inhibits migration and invasion through modulation of transforming growth factor beta-mediated mesenchymal properties in U87 and U251 cells.
abstract: In this study, we investigated the potential anticancer effects of calycosin against human glioblastoma cells, including the impacts on cell proliferation, apoptosis, and cell cycle distribution. We further studied its inhibitory activity on migration and invasion in U87 and U251 cells. Furthermore, transforming growth factor beta-mediated reductions of mesenchymal-associated genes/activators, matrix metalloproteinases-2, and -9 were detected in this process. Administration of calycosin in a glioblastoma xenograft model showed that calycosin could not only reduce tumor volume but also suppress transforming growth factor beta as well as its downstream molecules. These results revealed calycosin as a potential antitumor agent in human glioblastoma.
authors.affiliation: Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Xiao-hu
authors.initials: XH
authors.lastname: Nie
authors.affiliation: Nanchang University Medical College, Nanchang, Jiangxi, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Ou-yang
authors.affiliation: Department of Gastroenterology, The 98th Hospital of Nanjing Military Command, Huzhou, Zhejiang, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Xing
authors.affiliation: Spleen & Stomach Institute, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Dan-yan
authors.initials: DY
authors.lastname: Li
authors.affiliation: Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, People's Republic of China.
authors.forename: Ru-en
authors.initials: RE
authors.lastname: Liu
authors.affiliation: Bayi Brain Hospital, The Military General Hospital of Beijing PLA, Beijing, People's Republic of China.
authors.forename: Ru-xiang
authors.initials: RX
authors.lastname: Xu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007223:Infant; D007529:Isoflavones / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013329:Structure-Activity Relationship; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D007529:Isoflavones; D016212:Transforming Growth Factor beta; C121707:7,3'-dihydroxy-4'-methoxyisoflavone; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
keywords: calycosin; epithelial–mesenchymal transition (EMT); glioblastoma; invasion; matrix metalloproteinases (MMPs); migration